Using PSMA-PET imaging and genomic testing to obtain better information earlier in the disease course changes what clinicians can do with diagnosis and treatment planning.
Feature|Articles|March 18, 2026
Laurence Klotz, MD, FRCSC, reveals the impact of micro-ultrasound on his prostate cancer practice
Fact checked by: Patrick Campbell
The OPTIMUM randomized trial demonstrated that microultrasonography-guided biopsy is noninferior to MRI fusion-guided biopsy for detecting clinically significant prostate cancer, with a streamlined in-office workflow, a manageable learning curve, and substantially lower cost that may help address diagnostic access gaps worldwide.
Advertisement
Advertisement
Results from the
Related to this article
The registrational study is designed to evaluate the diagnostic performance of 68Ga-DOTA-RM2 vs histopathology in prostate cancer.
Juan Gómez-Rivas, MD, discusses barriers to PSMA-PET imaging and how disparities in access may affect prostate cancer staging and treatment planning.
In the phase 3 PACE-A trial, SBRT and prostatectomy showed similar 8-year disease control in localized prostate cancer, with lower rates of urinary incontinence after SBRT.
A limited market release of SpaceOAR Flex is expected to begin in the US later this year.
Better detection has changed prostate cancer care. Patients choosing radical treatment still need better protection from the disease returning.
A national study found that use of MRI before prostate biopsy increased in US hospitals from 2017 through the first half of 2026.
The UroOnc Minute: Neoadjuvant Therapy Before Radical Prostatectomy, With Isaac Y. Kim, MD, PhD, MBA
Isaac Y. Kim, MD, PhD, MBA, joins to discuss the evolving data surrounding neoadjuvant therapy before radical prostatectomy in prostate cancer.
Advertisement
Advertisement